Ep 86: Tudriqev (RP1) FDA Approval
Melanoma Matters

Ep 86: Tudriqev (RP1) FDA Approval

August 25, 202652 min

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data. It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.

Play episode

No transcript for this episode yet

You can still listen to it in the player. On episodes with a transcript, you can tap any word to see its meaning.